Compare AVTR & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVTR | SRRK |
|---|---|---|
| Founded | 1904 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.8B |
| IPO Year | 2019 | 2018 |
| Metric | AVTR | SRRK |
|---|---|---|
| Price | $14.44 | $56.23 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | $12.42 | ★ $56.17 |
| AVG Volume (30 Days) | ★ 11.2M | 981.1K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $6,552,200,000.00 | N/A |
| Revenue This Year | $1.05 | N/A |
| Revenue Next Year | $1.86 | $534.24 |
| P/E Ratio | $237.50 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.27 | $27.07 |
| 52 Week High | $15.93 | $58.49 |
| Indicator | AVTR | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 70.19 | 62.50 |
| Support Level | $13.08 | $45.81 |
| Resistance Level | $14.92 | $58.49 |
| Average True Range (ATR) | 0.42 | 2.38 |
| MACD | -0.05 | 0.63 |
| Stochastic Oscillator | 95.73 | 93.21 |
Avantor Inc provides products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company operates through two segments: Laboratory Solutions and Bioscience Production. It offers materials & consumables, equipment & instrumentation, and services & specialty procurement. Product groups include Equipment & Instrumentation, Services & Specialty Procurement, Proprietary Materials & Consumables, and Third-Party Materials & Consumables. Materials & consumables include high-purity chemicals and reagents, lab supplies, customized excipients, single-use assemblies, chromatography products, sample preparation kits, and fluid handling solutions. It operates in the Americas, Europe, and AMEA.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.